ABSTRACT
BACKGROUND: Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is an aggressive lymphoma with a very low incidence in western populations. OBJECTIVE: To review the clinicopathological features and outcome of a multicentre series of ENKTL in Spain. MATERIALS & METHODS: A multicentre retrospective study was performed based on cases of ENKTL, collected from 1995 to 2004, from 12 dermatology departments included in the Spanish Lymphoma Study Group. The clinical, histopathological, and evolutive features of all these cases were reviewed. RESULTS: Eighteen patients (three male, 15 female) with median age of 67 years were included in the study. The onset of lesions occurred in the nasal region in 11 patients and on the skin outside this region in the remaining cases. The observed lesions were clinically heterogeneous, corresponding to papules, plaques, and nodules, with or without ulceration. All patients except four received different polychemotherapy regimens, either alone (n = 11) or in combination with radiotherapy (n = 4). After a variable follow-up period (1-36 months), only two patients remained alive. One patient was recently diagnosed (four months ago) with ENKTL in the nasal region and the other presented with skin-limited disease. The median overall survival was 9.5 months. CONCLUSIONS: The results of this retrospective survey confirm that ENKTL is a rare subtype of lymphoma in the Spanish population. All patients showed an aggressive clinical course and poor prognosis, regardless of the initial clinical presentation. Prospective data on larger series of patients treated homogenously are needed to establish the best treatment modality.
Subject(s)
Lymphoma, Extranodal NK-T-Cell/pathology , Nose Neoplasms/pathology , Skin Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Female , Humans , Immunophenotyping , Lymphoma, Extranodal NK-T-Cell/therapy , Male , Middle Aged , Nose Neoplasms/therapy , Skin Neoplasms/therapy , Spain , Surveys and Questionnaires , Treatment OutcomeABSTRACT
La implicación de un mayor riesgo cardiovascular en algunas enfermedades dermatológicas ha sido evidenciada en las últimas décadas. Enfermedades como la psoriasis y el lupus eritematoso sistémico se encuentran actualmente incluidas en las guías de prevención de la enfermedad cardiovascular. Otras enfermedades como la alopecia androgénica, el síndrome del ovario poliquístico, la hidrosadenitis supurativa o el liquen plano disponen de numerosos estudios que apuntan a un mayor riesgo en estos pacientes, aunque todavía no han sido incluidas en estas guías. En el presente artículo se realiza una revisión de las evidencias que avalan esta asociación, con el objeto de advertir al clínico sobre la necesidad de un mayor control de los factores de riesgo cardiovascular en estos pacientes
The increased cardiovascular risk in some dermatological diseases has been demonstrated in recent decades. Diseases such as psoriasis and systemic lupus erythematosus are currently included in the guidelines for prevention of cardiovascular disease. Other diseases such as androgenic alopecia, polycystic ovary syndrome, hidradenitis suppurativa or lichen planus have numerous studies that point to an increased risk, however, they have not been included in these guidelines. In this article we review the evidence supporting this association, in order to alert the clinician to the need for greater control in cardiovascular risk factors in these patients
Subject(s)
Humans , Cardiovascular Diseases/epidemiology , Skin Diseases/complications , Risk Factors , Metabolic Syndrome/complications , Polycystic Ovary Syndrome/complications , Alopecia/complications , Hidradenitis/complications , Antiphospholipid Syndrome/complications , Lupus Erythematosus, Cutaneous/complications , Psoriasis/complicationsABSTRACT
The increased cardiovascular risk in some dermatological diseases has been demonstrated in recent decades. Diseases such as psoriasis and systemic lupus erythematosus are currently included in the guidelines for prevention of cardiovascular disease. Other diseases such as androgenic alopecia, polycystic ovary syndrome, hidradenitis suppurativa or lichen planus have numerous studies that point to an increased risk, however, they have not been included in these guidelines. In this article we review the evidence supporting this association, in order to alert the clinician to the need for greater control in cardiovascular risk factors in these patients.
